Elan Corp May 30, 1999. This Ireland based specialty pharmaceutical firm appears poised for tremendous sales and earnings expansion over the next few years. Elan will leverage their proven success in new drug delivery technologies to commercialize their own proprietary portfolio of promising new neurological and other drugs. New products being introduced by Elan licensees include Verelan PM antihypertensive and Prostep OTC nicotine. Elan itself plans to launch a bevy of new drugs, such as Zonegran for epilepsy, Ziconotide for acute and malignant pain, Miguard for migraine headaches, Neuroblic for cervical dystonia and Antegren foe multiple sclerosis; contingent on FDA approval. In 1999, Elan is expected to see a profit of $2.49 per share, representing an improvement from the prior year deficit of minus $9.83 per share. Forecast for year 2000 earnings at Elan are expected to have a rate of growth greater than anticipated for the broad market. I can say now that I missed the chance to get in on this stock last year when it was trading at about $49, but right now it seems to be on the right track for the future, especially if the FDA approves their upcoming drugs. The drugs are very promising. If every thing goes as expected, you would be looking at a price point of $90-$95 a share by the end of 2000 to mid 2001. Ticker: ELN. George

Resources Online Investing - Online Investing is a wonderful guide for using the Internet to find, research, and buy winning stocks. Jon D. Markman, managing editor at MSN MoneyCentral Investor, writes that the Internet makes it easy to build a highly profitable portfolio. Merck - Learn about this pharmaceutical kingpin.     Our editorial goal is to provide a forum for investment ideas. Our articles, columns, and other features should not be construed as investment advice, nor does their appearance imply an endorsement by Kolias & Co of any specific security or trading strategy. An investor's best course of action must be based on individual circumstances.    Privacy Policy | © 1998-2002, Kolias & Co | Liability Disclaimer